A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2600 participants.

Also called NCT06033950

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,600 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06033950
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Brazil, Canada, Croatia, Czechia, Greece, Hungary, Italy, Japan, Poland, Spain, Sri Lanka, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06033950. Randomized; quadruple masking; primary purpose treatment. Start 2024-08-20 (actual); primary completion 2026-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
Acronym
FINALITY-HF
Condition
Heart Failure
Intervention (Drug)
Finerenone
Intervention (Drug)
Placebo
Lead sponsor
Colorado Prevention Center (class: other)
Collaborator
St. Luke's Hospital, Kansas City, Missouri (class: other)
Collaborator
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma (class: industry)

Record details

Record id
cardio:ct-nct06033950
Content hash
e82253e9eeb1c628c07e1479a509a2e452fde8dff800e88eb8fff5c4b563c623